Australia’s Essential Principles are changing: what Manufacturers and Software as a Medical Device (SaMD) Developers need to know
Australia’s medical device landscape is continuing to evolve, and one of the most significant developments on the horizon involves the Essential Principles (EPs) – the core safety and performance requirements that all medical devices must satisfy before they can be supplied in Australia.
The Therapeutic Goods Administration (TGA) has released proposed updates to the EPs, signalling a move toward stronger international harmonisation, greater transparency, and a deeper emphasis on lifecycle safety. While no regulatory changes have yet taken effect, the proposals offer valuable insight into how the regulatory framework may shift in the future.
Understanding the EP’s
The EPs form the foundation of medical device regulation in Australia. They outline what every device must demonstrate in relation to safety, performance, material and biological compatibility, labelling and Instructions for Use (IFU), and the level of clinical evidence needed to support its intended purpose.
These requirements apply broadly, covering both high-level principles – such as achieving an appropriate benefit-risk balance and ensuring safe design – as well as more specific technical considerations, including contamination control, usability, electrical and software safety, and the clarity of information provided to users.
Manufacturers typically demonstrate compliance through design and development documentation, verification and validation activities, ISO 14971 risk management, labelling and IFU content, and Quality Management System (QMS) controls.
What the TGA Is Proposing to Change
The TGA’s consultation proposed modernising a number of EPs to better align with the General Safety and Performance Requirements (GSPRs) under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). The aim is not to replicate the European framework, but to bring Australian requirements closer to contemporary international expectations while maintaining the flexibility of the current EP structure.
A key theme across the proposed updates is the strengthening of general safety concepts. This includes clearer articulation of benefit-risk considerations, enhanced expectations around information necessary for safe use, and more explicit treatment of “device lifetime” and how it should be supported and communicated.
Several design and construction-related EPs were also flagged for revision. These relate to material and chemical safety, microbial and contamination control, environmental considerations, interoperability, and performance characteristics of active and software-driven devices. These updates reflect the growing complexity of modern medical technologies and the increasing reliance on software and interconnected systems.
Significant attention was given to EP13, which governs labelling and IFUs. The proposed changes introduce clearer expectations around reusability, cleaning and refurbishment, hardware and software compatibility, and improved clarity for devices intended for lay users. Elements of global Unique Device Identification (UDI) practices are also embedded throughout this section.
While many of the proposed elements draw from the MDR/IVDR, the TGA has carefully adapted them to the Australian context. Several EPs – such as those related to clinical evidence – are expected to remain largely unchanged.
Implications for Manufacturers and Sponsors
Although the consultation has now closed, the proposed updates provide an early indication of how future regulatory expectations may evolve. Manufacturers and sponsors may find it useful to understand the direction of the proposed changes, particularly in relation to benefit–risk justification, material and biological safety, labelling clarity, and software-related requirements.
The proposals also highlight the TGA’s increasing focus on real-world usability, transparency and compatibility – areas of particular relevance to software-based medical devices. For SaMD developers, the emphasis on software behaviour, update processes, cybersecurity and system interoperability reinforces the need for robust technical documentation and holistic lifecycle management.
Labelling and IFUs may become a key area of future refinement. Broader expectations around warnings, reprocessing, compatibility and device identification signal a likely shift toward more detailed and transparent information for end users.
Where Things Stand Now the Consultation Has Closed
With the consultation period now closed, the sector is awaiting the TGA’s review of stakeholder feedback and its final position. Once the TGA releases its outcomes – along with any transition timeframes or amendments to the regulations – manufacturers and SaMD developers will have clearer guidance on how to prepare.
In the meantime, organisations may find value in reviewing the proposals and considering how potential updates could intersect with their existing documentation, processes and product portfolios. Staying informed now will support a smoother transition once the TGA’s final decisions are published.
Final Thoughts
The TGA’s proposed updates to the Essential Principles mark an important evolution in Australia’s approach to medical device regulation. By strengthening alignment with global frameworks and refining key safety and performance expectations, the changes aim to support device quality, clarity and patient safety.
For now, the focus should be on understanding the proposals while awaiting the TGA’s final determinations. Once published, these outcomes will guide any future planning or updates needed.
If you would like assistance reviewing the proposed EP updates or assessing how potential changes may affect your product portfolio, KD&A is here to help.
